Output list
Conference presentation
Evidence for direct and indirect modulation of haemostatic factors by miR-494
Published 2017
International Society on Thrombosis and Haemostasis 2017, 08/07/2017–13/07/2017, Berlin, Germany
High oestrogen levels during pregnancy are associated with acquired deficiencies in the anti-coagulation factor, Protein S, with pregnant women at an increased risk of developing venous thrombosis...
Conference presentation
MicroRNA-494 promotes thrombosis by targeting multiple coagulation factors
Published 2015
1st International Symposium on Functional Nucleic Acids: From Laboratory to Targeted Molecular Therapy, 26/11/2015–27/11/2015, Murdoch University, Perth
Poster presentation
Conference presentation
APMAT, A Multi-Centre observational study of patients with microangiopathic thrombocytopenia
Published 2015
Science on the Swan, 21/04/2015–23/04/2015, Perth, Western Australia
Microangiopathic Thrombocytopenia (MAT) is a rare but often fatal collection of disorders. The disorder can be categorised by distinct disease states including thrombotic thrombocytopenia purpura (TTP) and atypical haemolytic uremic syndrome. Clinical presentations of MAT, however, often represent di_erent but related aetiologies from overlapping syndromes. TTP has an incidence rate of 2-15 cases per million people-years. When left untreated, it has a mortality rate of ~90%; with treatment the mortality rate remains relatively high (~20%). Moreover, TTP patients often su_er a high rate of recurrent relapses. Aetiologically, TTP is a result of insu_cient cleavage of high molecular weight von Willebrand Factor multimers due to abrogated ADAMTS13 activity. Current diagnosis lacks disease _delity and temporal resolution, making clinical management di_cult. There exists, therefore, a need for a faster and standardised clinical management for TTP. The APMAT project is a retrospective study instigated to _ll this information gap. The study aims to collect a total of 150 patient samples from various study centres in the Asia-Paci_c (AP) region, with WACTH Murdoch University acting as a repository, co-ordinating and R&D centre. Five key outcomes of APMAT will be: 1. Develop the APMAT research network protocol, 2. Formation of an AP medical advisory panel of APMAT experts for individual clinical advice, 3. Establish a clinical adjudication committee for independent classi_cation of MAT patients, 4. Standardise laboratory testing for ADAMTS13 and any other novel assays in the AP region, 5. Facilitate basic science and translational clinical research into MAT.
Conference presentation
Platelet activation releases mature miR-494 in microparticles
Published 2015
1st International Symposium on Functional Nucleic Acids: From Laboratory to Targeted Molecular Therapy, 26/11/2015–27/11/2015, Murdoch University, Perth
Poster presentation
Conference presentation
Published 2015
1st International Symposium on Functional Nucleic Acids: From Laboratory to Targeted Molecular Therapy, 26/11/2015–27/11/2015, Murdoch University, Perth
Poster presentation
Conference presentation
In silico prediction of microRNA binding sites in haemostatic factors
Published 2015
Science on the Swan, 21/04/2015–23/04/2015, Perth, Western Australia
Poster presentation
Conference presentation
In silico Prediction of microRNA Binding Sites in Haemostatic factors
Published 2015
International Society on Thrombosis and Haemostasis (ISTH) 2015, 20/06/2015–25/06/2015, Toronto, Canada
Poster presentation
Conference presentation
Published 2015
International Society on Thrombosis and Haemostasis (ISTH) 2015, 20/06/2015–25/06/2015, Toronto, Canada
Poster presentation
Conference presentation
Probing miR-494 function in coagulation
Published 2015
Science on the Swan, 21/04/2015–23/04/2015, Perth, Western Australia
Poster presentation
Conference presentation
Update on Microangiopathic thrombocytopenia - diagnosis and treatment
Published 2014
Asian Pacific Society Thrombosis and Haemostasis Scientific Meeting, 09/10/2014–11/10/2014, Hanoi, Vietnam
No abstract available